Literature DB >> 30320597

Diagnostic Accuracy of Phenotype Classification in Duchenne and Becker Muscular Dystrophy Using Medical Record Data1.

Jennifer G Andrews1, Molly M Lamb2, Kristin Conway3, Natalie Street4, Christina Westfield5, Emma Ciafaloni6, Dennis Matthews7, Christopher Cunniff8, Shree Pandya6, Deborah J Fox5.   

Abstract

Dystrophinopathies are caused by mutations in DMD resulting in progressive muscle weakness. They are historically divided into the more severe Duchenne (DMD) and milder Becker (BMD) muscular dystrophy phenotypes. Classification is important for research and clinical care. The purpose of this study was to describe a multi-variable approach to classifying cases from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) and to assess the accuracy of the diagnostic classification scheme. We used age at loss of mobility, molecular testing results, and age at symptom onset to classify cases as having DMD or BMD and to assess sensitivity and specificity. Mobility status showed low sensitivity and high specificity for predicting DMD (65.5% and 99.3%, respectively) and BMD (62.8% and 97.7%, respectively) phenotypes. Molecular testing showed 90.9% sensitivity and 66.4% specificity for DMD; 76.3% sensitivity and 90.0% specificity for BMD. Age of onset predicted DMD with sensitivity of 73.9% and specificity of 69.0%; BMD had 99.7% specificity and 36.7% sensitivity. Mobility status, molecular test results, and age at symptom onset are important but inconsistent measures for accurately classifying individuals into DMD or BMD phenotypes. These results have implications for prognosis in newly diagnosed individuals and for classifying phenotype in clinical trials.

Entities:  

Keywords:  Becker; Duchenne; Muscular dystrophies; diagnostic accuracy; dystrophinopathy; phenotype

Mesh:

Year:  2018        PMID: 30320597      PMCID: PMC6367719          DOI: 10.3233/JND-180306

Source DB:  PubMed          Journal:  J Neuromuscul Dis


  50 in total

1.  Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort.

Authors:  K M Dent; D M Dunn; A C von Niederhausern; A T Aoyagi; L Kerr; M B Bromberg; K J Hart; T Tuohy; S White; J T den Dunnen; R B Weiss; K M Flanigan
Journal:  Am J Med Genet A       Date:  2005-04-30       Impact factor: 2.802

2.  Analysis of splicing parameters in the dystrophin gene: relevance for physiological and pathogenetic splicing mechanisms.

Authors:  M Sironi; U Pozzoli; R Cagliani; G P Comi; A Bardoni; N Bresolin
Journal:  Hum Genet       Date:  2001-07       Impact factor: 4.132

3.  Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity.

Authors:  A Carsana; G Frisso; M R Tremolaterra; R Lanzillo; D F Vitale; L Santoro; F Salvatore
Journal:  Ann Hum Genet       Date:  2005-05       Impact factor: 1.670

4.  Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.

Authors:  Birol Balaban; Dennis J Matthews; Gerald H Clayton; Terri Carry
Journal:  Am J Phys Med Rehabil       Date:  2005-11       Impact factor: 2.159

5.  Frameshift deletion mechanisms in Egyptian Duchenne and Becker muscular dystrophy families.

Authors:  Nasser A Elhawary; Elhawary Nasser A; Rabah Mohamad Shawky; Nemat Hashem
Journal:  Mol Cells       Date:  2004-10-31       Impact factor: 5.034

6.  Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis.

Authors:  O Yilmaz; A Karaduman; H Topaloğlu
Journal:  Eur J Neurol       Date:  2004-08       Impact factor: 6.089

7.  Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.

Authors:  W D Biggar; V A Harris; L Eliasoph; B Alman
Journal:  Neuromuscul Disord       Date:  2006-03-20       Impact factor: 4.296

8.  Dystrophin in frameshift deletion patients with Becker muscular dystrophy.

Authors:  S B Gangopadhyay; T G Sherratt; J Z Heckmatt; V Dubowitz; G Miller; M Shokeir; P N Ray; P N Strong; R G Worton
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

9.  Intronic breakpoint definition and transcription analysis in DMD/BMD patients with deletion/duplication at the 5' mutation hot spot of the dystrophin gene.

Authors:  F Gualandi; P Rimessi; C Trabanelli; P Spitali; M Neri; T Patarnello; C Angelini; S C Yau; S Abbs; F Muntoni; E Calzolari; A Ferlini
Journal:  Gene       Date:  2006-01-24       Impact factor: 3.688

Review 10.  Dystrophin and mutations: one gene, several proteins, multiple phenotypes.

Authors:  Francesco Muntoni; Silvia Torelli; Alessandra Ferlini
Journal:  Lancet Neurol       Date:  2003-12       Impact factor: 44.182

View more
  6 in total

1.  Selected clinical and demographic factors and all-cause mortality among individuals with Duchenne muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking, and Research Network.

Authors:  Pangaja Paramsothy; Yinding Wang; Bo Cai; Kristin M Conway; Nicholas E Johnson; Shree Pandya; Emma Ciafaloni; Katherine D Mathews; Paul A Romitti; James F Howard; Catharine Riley
Journal:  Neuromuscul Disord       Date:  2022-04-30       Impact factor: 3.538

2.  Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non-ambulatory males with Duchenne muscular dystrophy from MD STARnet.

Authors:  Russell J Butterfield; Sergey Kirkov; Kristin M Conway; Nicholas Johnson; Dennis Matthews; Han Phan; Bo Cai; Pangaja Paramsothy; Shiny Thomas; Marcia L Feldkamp
Journal:  Muscle Nerve       Date:  2022-01-20       Impact factor: 3.852

3.  A population-based study of scoliosis among males diagnosed with a dystrophinopathy identified by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).

Authors:  Kristin M Conway; Amber Gedlinske; Katherine D Mathews; Seth Perlman; Nicholas Johnson; Russell Butterfield; Man Hung; Jerry Bounsanga; Dennis Matthews; Joyce Oleszek; Paul A Romitti
Journal:  Muscle Nerve       Date:  2021-12-01       Impact factor: 3.852

4.  Differentiation of Pediatric-Onset Duchenne and Becker Muscular Dystrophy Subphenotypes Using Data from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet).

Authors:  Jennifer G Andrews; Molly M Lamb; Kristin M Conway; Natalie Street; Christina Westfield; Emma Ciafaloni; Dennis Matthews; Shree Pandya
Journal:  J Neuromuscul Dis       Date:  2022

5.  Health-Related Quality of Life and Emotional Distress Among Mothers of Sons With Muscular Dystrophy as Compared to Sex- and Age Group-Matched Controls.

Authors:  Jamie L Jackson; Christina X Korth; Carine E Leslie; Jennifer Cotto; May Ling Mah; Kan Hor; Linda Cripe; Samiah Al-Zaidy; Eric M Camino; Kathleen Church; Kelly J Lehman; Victoria Shay; Jerry R Mendell
Journal:  J Child Neurol       Date:  2020-10-09       Impact factor: 1.987

6.  Study of Clinical Features and Diagnosis Pattern of Duchene Muscular Dystrophy in Southern India.

Authors:  Nigama Chandra Sattenapalli; Anka Rao Areti; S N Koteswara Rao G; Uma Sankar Kulandaivelu; Rajasekhar Reddy Alavala; Ravi Manne
Journal:  J Neurosci Rural Pract       Date:  2022-01-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.